Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:21:39.313Z.
Calculation as of: 2026-10-06T17:21:39.313Z.
Quote observation: 2026-10-06T17:01:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f130e36c5816a2cced4d00ccb7d778b7baaa6bfdcaf5b95b3974dc9f748ee68d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$2.53M
PS Ratio
0.43
TTM Avg
0.51
3Y Avg
25.58
5Y Avg
970.72
Market Cap
$2.37M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.31M
PS Ratio
769.98
TTM Avg
1295.61
3Y Avg
740.97
5Y Avg
482.27
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| FibroBiologics, Inc. Common Stock (FBLG) | $2.54M | N/A | N/A | N/A | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.53M | 0.43 | 0.51 | 25.58 | 970.72 |
| Jaguar Health, Inc. (JAGX)vs › | $2.50M | 0.09 | 0.09 | 0.25 | 0.61 |
| Nuwellis, Inc. (NUWE)vs › | $2.63M | 0.29 | 0.14 | 4.27 | 13.74 |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.41M | N/A | N/A | N/A | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.37M | N/A | N/A | N/A | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.36M | 3.66 | 140.58 | 558.30 | 558.30 |
| iSpecimen Inc. (ISPC)vs › | $2.72M | 5.83 | 1.16 | 0.59 | 1.24 |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.31M | 769.98 | 1295.61 | 740.97 | 482.27 |
| GeoVax Labs, Inc. (GOVX)vs › | $2.27M | N/A | 1.63 | 5.61 | 81.97 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-31 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-31 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
